FDA grants RMAT designation to OCU410 after Phase 2 geographic atrophy results
OCU410 receives FDA RMAT designation after Phase 2 data showed 31% slower geographic atrophy lesion growth with one gene therapy dose.
Pharma & Biotech
Medical Devices & Diagnostics
How Science Corporation’s PRIMA system restores prosthetic central vision in advanced AMD
Science Corporation launches CE-marked PRIMA in Europe, but reimbursement, specialist training and real-world outcomes will determine access.
Pharma & Biotech
Why Bausch + Lomb stopped its BL1107 neuroprotective glaucoma eye-drop program
Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.
Pharma & Biotech
Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.
Pharma & Biotech
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Pharma & Biotech
Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.